Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 18712.0 | 26 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 23367.5 | 46 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 6998.0 | 35 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 5760.5 | 46 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 420.0 | 47 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 5418.5 | 28 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 6509.0 | 43 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 6790.0 | 31 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 748.0 | 48 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MMP-1 | 3586.0 | 65 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 5822.0 | 41 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 8487.0 | 36 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 2302.5 | 60 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 2328.0 | 43 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 7073.0 | 36 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 5444.5 | 38 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 3868.0 | 33 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 2535.0 | 22 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 5268.0 | 30 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 5009.0 | 23 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 400.5 | 36 | |
N2759 | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 813.5 | 20 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 5873.5 | 50 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 8602.0 | 36 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MMP-1 | 1133.0 | 33 |